Digitalizing your market access processes will leave you wondering how you managed the “old way” for so long
In recent years, healthcare has gone digital: from artificial-intelligence-driven diagnostics, through to wearable technology and health apps. The pharmaceutical industry has also embraced digital efficiencies relating to internal processes, from drug discovery to drug development and packaging.
Arguably, market access divisions have been a little late to the game. While digital technology has been applied in various ways to external communications and payer engagement tools, it is only recently that market access teams have caught up to the digital enhancements of their internal processes.
Digitalization is transforming market access processes by providing new solutions for:
- driving proactive planning and agility
- enhancing real-time decision-making
- accelerating cross-functional productivity
- linking global thinking with local needs and implementation.
Delegates at ISPOR Europe 2019 will see how breakthrough digital applications are transforming internal market access decision-making and resource allocation
ISPOR Europe 2019 provides a perfect opportunity to examine the digital transformation of your market access process. Our expert team will be in Copenhagen to help you evaluate how digital applications will help you realize your market access vision and empower you to optimize your entire global portfolio, evidence generation plans, health technology assessment submissions, and real-time payer insights.
Start your digital transformation journey at our ISPOR Europe 2019 drinks reception
On Monday 4 and Tuesday 5 November, from 6pm to 7pm, we are hosting a free drinks reception for market access professionals who are interested in digital transformation. Join us on booth C02-14 where our senior team will be pleased to speak with you about using digital applications to unlock and optimize product value, from early development through to successful country submissions.
“In recent years we have seen how digital technology has been harnessed to improve health outcomes. With the rapidly evolving market access landscape, we are now on the cusp of a huge acceleration in the use of digital applications to explore value options, gain strategic advantage, and provide innovative market access solutions. It’s inevitable that digital applications will be used within market access. At ISPOR Europe 2019 I would encourage everyone to evaluate how digital technology can better enable processes and prioritize requirements. Only then can you ensure that your company fully unlocks and optimizes product value and elevates market access competitiveness.”
“Right now we are seeing an unprecedented uptake in our digital applications, which are helping to transform the market access processes of leading pharmaceutical and biotechnology companies. Our secure, scalable, cloud computing is supporting their competitive advantage, and it’s a very exciting time for us and the profession. We our experts in overcoming the challenges of digital adoption and our clients have seen that the rewards are more than worth it. I’d encourage any market access professionals who are keen to find out more about partnering with PRMA Consulting to meet us on our booth C02-14 in Copenhagen, or to read some of our case studies and get in touch.”
Free eBook. How to accelerate the generation of simultaneous, high-quality HTA submissions.
ISPOR Europe 2019: Educational symposium
Capturing multi-stakeholder perspectives on assessing the long-term clinical benefit of cancer immunotherapy
A conceptual checklist has been developed that captures multi-stakeholder perspectives on assessing the long-term clinical benefit of cancer immunotherapy. The checklist used input from multi-country advisory panels into the key issues to be addressed by both manufactures and payers.
Immunotherapy represents a significant breakthrough in the treatment of cancer across multiple tumor types and patient populations. Immunotherapies differ from traditional cancer therapies as they do not target cancer directly, but instead target the body’s immune system. This changes the mechanism of survival in treated patients, as well as the shape of the survival curve and smoothing estimators of the hazard function. This is the effect known as the “plateau” or “tail of the curve”: the flattening of the overall survival Kaplan-Meier curve typically seen after 2 years of follow-up. However, there are widely differing opinions on how best to demonstrate and convey the longer-term health gains of immunotherapies at both regulatory and health technology assessment (HTA) filing, which impacts access for patients worldwide.
In the research to be presented, an international, multi-stakeholder steering committee was formed comprising 9 experts: payers, economists, and clinicians from the US, UK, France, Italy, and Sweden. Following a review of published literature and technology assessments, key issues and challenges in measuring the long-term clinical benefit specific to cancer immunotherapy were identified. Double-blinded, country-level, multi-stakeholder panels were then convened in the US, UK, France, Germany, and Sweden to refine the key issues and how to address them.
The challenges identified relate to three areas: (1) mechanism of action (underlying biology, pseudo progression); (2) limited data at launch (immature overall survival, response, surrogate endpoints); and (3) the analytic methodology (non-proportional hazards and model structure, the plateau in the survival curve, heterogeneity in treatment effect and patient outcomes). To focus evidence generation on addressing those issues systematically, a conceptual checklist has been developed that manufacturers can use to produce structured, multi-stakeholder evidence that addresses the key challenges for HTAs of cancer immunotherapies. Applying a consistent approach to evidence generation, HTA submissions, and assessments will help to improve estimation and consistency around the longterm clinical benefit of cancer immunotherapies.
All work relating to the development of the source guidance document and current position paper was funded by Bristol-Myers Squibb. The sponsor was not involved in the analysis or interpretation of the guidance generated.
Sponsor: Bristol-Myers Squibb
Moderator: David Sykes, MSc. PRMA Consulting, UK
Speakers: Louis P Garrison, PhD. University of Washington, US
Philip McEwan, PhD. Swansea University, UK
Gustav Ullenhag, PhD. Consultant and Associate Professor in Oncology, Uppsala University Hospital, Sweden